SCHEMBL7106781

SCHEMBL7106781

O=C(Nc1nc2ccccc2c2c1ncn2CCOCc1cc2ccccc2o1)C(Cl)(Cl)Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
ATM Q13315 1/20 0.36
HDAC6 Q9UBN7 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 3/20 0.34
RXFP1 Q9HBX9 2/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAPT P10636 6/20 0.34
TLR7 Q9NYK1 1/20 0.34
NPC1 O15118 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
LMNA P02545 3/20 0.33
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6108450 0.81 ALDH1A1 (0.40) ALDH1A1HPGDSMN1; SMN2KDM4EGLA
SCHEMBL6698410 0.80 TLR7 (0.49) SMN1; SMN2HDAC6POLBMAPTTLR7
SCHEMBL6702919 0.77 ALDH1A1 (0.36) ALDH1A1HPGDSMN1; SMN2KDM4EGLA
SCHEMBL6696791 0.75 AGXT (0.40) SMN1; SMN2GAAKMT2APOLBTSHR
SCHEMBL6104311 0.69 TLR7 (0.43) ALDH1A1HPGDSMN1; SMN2KDM4EGLA
SCHEMBL6107003 0.66 TLR7 (0.58) TLR7
SCHEMBL24263097 0.65 TLR7 (0.58) ALDH1A1KDM4EATMKMT2APOLB
SCHEMBL6702016 0.65 LMNA (0.41) SMN1; SMN2GAAKMT2APOLBTLR7
SCHEMBL6108474 0.64 KDM4E (0.37) ALDH1A1HPGDSMN1; SMN2KDM4EGLA
SCHEMBL6104573 0.64 SCD (0.38) ALDH1A1HPGDSMN1; SMN2KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664260-B2 Viricides; anticarcinogneic agents; induction cytokine biosynthesis 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
EP-1339715-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-03 EP disclosed
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
WO-2002046193-A2 HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065005-A1 Heterocyclic ether substituted imidazoquinolines IFNG, IL2, IRF3 ALDH1A1 2486/4885HPGD 560/4885SMN1; SMN2 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.